Dong-A ST Co., Ltd. (KRX:170900)

Market Cap	336.87B -19.3%
Revenue (ttm)	860.94B +15.4%
Net Income	8.69B
EPS	888.73
Shares Out	9.64M
PE Ratio	39.33
Forward PE	11.88
Dividend	666.67 (1.91%)
Ex-Dividend Date	Mar 10, 2026

Volume	5,472
Open	35,300
Previous Close	34,900
Day's Range	34,550 - 35,300
52-Week Range	31,600 - 56,381
Beta	0.42
Analysts	Buy
Price Target	56,952.38 (+62.95%)
Earnings Date	Oct 27, 2026

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 1,649
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2025, Dong-A ST's revenue was 808.78 billion, an increase of 15.89% compared to the previous year's 697.87 billion. Losses were -28.59 billion, 2237.8% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for 170900 stock is "Buy." The 12-month stock price target is ₩56,952, which is an increase of 62.95% from the latest price.

Price Target

₩56,952

(62.95% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error